| abstract |
The present invention relates to novel 3-aminopropanamide selective androgen receptor degrading agent (SARD) compounds, pharmaceutical compositions, and prostate cancer, advanced prostate cancer, castration resistant prostate cancer, androgenic alopecia, or other Androgen receptor-full length (AR) including their use in the treatment of hyperandrogenic skin disease, Kennedy disease, amyotrophic lateral sclerosis (ALS), and uterine fibroids, as well as pathogenic or resistant mutations in subjects -FL), AR-splice variants (AR-SV), and methods of reducing the level of AR pathogenic polyglutamine (polyQ) polymorphisms. [Selection] Figure 9 |